Use of the PFA-100(TM) apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents

Thrombosis and Haemostasis

Volumn 83, Issue 4, 2000, Pages 540-544

  Hézard, Nathalie ^a   Metz, Damien ^a   Nazeyrollas, Pierre ^a   Droulle, Chantal ^a   Elaerts, Jacques ^a   Potron, Gérard ^a   Nguyen, Philippe ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Acetyl salicylate acid; c7E3 Fab; Monitoring; PFA 100(TM); Platelet

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTICOAGULANT AGENT; COLLAGEN; HEMOGLOBIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DEVICE; FEMALE; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RELIABILITY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; BLEEDING; BLOOD; BLOOD CELL COUNT; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; EQUIPMENT DESIGN; INSTRUMENTATION; LUNG EMBOLISM; MICROCOMPUTER; MIDDLE AGED;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD CELL COUNT; COLLAGEN; EPINEPHRINE; EQUIPMENT DESIGN; FEMALE; HEMOGLOBINS; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICROCOMPUTERS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PULMONARY EMBOLISM;

EID: 0034168022     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613859     Document Type: Article

References (35)

1. Smith JW, Steinhubl SR, Lincoff M, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-25.
2. Bernardi MM, Califf RM, Kleiman NS, Ellis SG, Topol EJ, for the TAMI Study Group. Prolonged bleeding times do not predict hemorrhagic events in patients receiving c7E3 GPIIb/IIIa platelet antibody. Circulation 1992; 86: 1-260. Abstract.
3. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet GPIIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76-81.
4. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E; for the TIMI 12 Investigators. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist. Sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 1998; 97: 340-9.
5. Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud ARZ, Broderick TM, Abbotsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Toplol EJ; for the Oral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit Thrombosis (ORBIT) Trial Investigators Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral Xemilofiban, Circulation 1998; 98: 1268-78.
6. Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenhurg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bonn D, Rutsch W, Schaible TF, Weisman HF, Kloolwijk P, Nijsscn KM, Stibbe J, de Feyter PJ; and the European Cooperative Study Group. Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
7. Kleiman NS, Ohman EM, Califf RM, George BS, Kereikaes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
8. Wagner C, Mace K, Mascelli MA, DeRita R, Lance E, Weisman H, Ghrayeb J, Jordan R. Pharmacodynamics of ReoPro (c7E3 Fab): free plasma levels determine clinical efficacy. Thromb Haemost 1997; S:7-8. Abstract.
9. Riederer MA, Steiner B. The extend of platelet aggregation is dependent on the free GPIIb/IIIa concentration and not the % receptor occupancy. Thromb Haemost 1997; S:6-7. Abstract.
10. Anderson DR, Zayed E, Embree J, Theroux P, Steiner B. Flow cytometry as a quantitative measure of the antiplatelet activity of a glycoprotein IIb/IIIa inhibitor. Blood 1997; 86: 893. Abstract.
11. Liu CZ, Hur BT, Huang TF. Measurement of glycoprotein IIb/IIIa blockade by cytometry with fluorescein isothiocyanate-conjugaled crotavirin, a member of disintegrins. Thromb Haemost 1996; 76: 585-91.
12. Hézard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphard S, Elaerts J, Potron G. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999; 81: 869-73.
13. Mascelli MA, Worley S, Veriabo NJ, Lance HT, Mack S, Schaible T, Weisman HF, Jordan RE. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation 1997; 96: 3860-66.
14. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-7.
15. Mammen EF, Comp PC, Gossclin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ,. PFA-100™ System: a new method for assessment of platelet dysfunction. Sem Thromb Haemost 1998; 24: 195-202.
16. Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thromb Haemost 1996; 2: 241-9.
17. Fressinaud E, Veyradier A, Truchaud F, Martin I, Buyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
18. Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Throm Haemost 1999; 82: 35-9.
19. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyser - PFA-100™. Sem Thromb Haemost 1995; 21: 106-12.
20. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 294: 927-9.
21. Böhner J, von Pape KW, Wiebersinsky W, Alan E, Wuttke M, Dölp R. Serial assessment of platelet function following a single 300 mg dose of acetylsalicylic acid. Ann Haematol 1997; 74: 136. Abstract.
22. Borries M, Söhngen D, Englisch C, Schoebel FC, Stein D, Stiegler H, Boogen C, Strauer BE, Leschke M. Measurement of the effect of aspirin and ticlopidin on platelet function with a simple in vitro bleeding test. Ann Haematol 1997; 74: 137. Abstract.
23. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the Platelet Function Analyzer (PFA-100®). Clin Appl Throm Haemost 1999; 5: 122-30.
24. Borries M, Söhngen D, Englisch C, Schoebel FC, Stein D, Fischer Y, Boogen C, Strauer BE, Leschke M. Platelet activation in patients with coronary artery disease before and after PTCA an aspirin medication. Ann Haematol 1997; 74: 73. Abstract.
25. Zimmerman M, Ittner KP, Grobecker H, Alban S. Do subcutaneously applied unfractionated heparin and low molecular weight heparins influence platelet function assessed by PFA-100™? Ann Haematol 1998; 76: 255. Abstract.
26. Cardinal DC, Flower RJ. The electronic aggregometer : a novel device of assessing platelet behavior in blood. J Pharmacol Meth 1980; 3: 1350-8.
27. Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.
28. Casterella PJ, Kereiakes DJ, Steinhubl SR, Raymond RE, Topol EJ, Patel K, Mueller M, Rosenthal M, Teirstein PS. Use of the rapid functon analyzer (RPFA) to evaluate platelet function in patients receiving incremental bolus dosing of abciximab (ReoPro™) during percutaneous coronary interventions (PCI). J Am Coll Cardiol 1999; 33 sup: 39A. Abstract.
29. Theroux P. Gosselin G, Nasmith J, Cox D, Fitzgerald D, Burns D, Anders R. The Accumetrics rapid function analyzer (RPFA™) to monitor platelet aggregation during oral administration of a GPIIb/IIIa antagonist. J Am Coll Cardiol 1999; 33 sup: 330A. Abstract.
30. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Miltlboeck M, Schreiner W, Losen U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
31. Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Volksw D, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
32. Gawaz, M, Neumann FJ, Ott I, May A, Schöming A. Platelet activation and coronary stem implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-85.
33. Neuman FJ, Gawaz M, Ott I, May A, Mössmer G, Schöming A. Prospective evaluation of haemostatic predictors of subacute stem thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 15-21.
34. Rupprecht HJ, Darius H, Borkowski U, Voigtländer T, Nowak B, Genth S, Meyer J. Comparison of antiplatelet effects of aspirin, ticlopidin, and their combination after stent implantation. Circulation 1998; 97: 1046-52.
35. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312-14.